These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
6. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403 [TBL] [Abstract][Full Text] [Related]
8. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Adusumilli PS; Chan MK; Hezel M; Yu Z; Stiles BM; Chou TC; Rusch VW; Fong Y Ann Surg Oncol; 2007 Jan; 14(1):258-69. PubMed ID: 17080237 [TBL] [Abstract][Full Text] [Related]